Trial
NCT00947167
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Pamela L. Kunz
Collaborators
Genentech, Inc.
Condition
Neuroendocrine Tumors
Intervention
pertuzumab
Why stopped
Extreme toxicity of Pertuzumab and Erlotinib combination
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-03